Literature DB >> 17040622

Gene therapy for ovarian cancer.

Kristopher J Kimball1, T Michael Numnum, Rodney P Rocconi, Ronald D Alvarez.   

Abstract

Ovarian cancer remains the leading cause of death due to gynecologic cancer in women in the United States. Gene and viral-based therapies represent novel therapeutic approaches for cancer. The manipulation of genetic content of tumor cells toward a therapeutic end has been divided into several general strategies, including molecular chemotherapy, mutation compensation, immunopotentiation, and virotherapy. Improvements in delivery vehicles and in evaluation of gene transfer and viral replication remain important areas of investigation. We highlight the most recent advances in these novel therapeutic approaches for ovarian cancer and include a summary of recent clinical trials.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17040622     DOI： 10.1007/s11912-006-0073-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  45 in total

1.  Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.

Authors:  Gerd J Bauerschmitz; Kilian Guse; Anna Kanerva; Artur Menzel; Isabell Herrmann; Renee A Desmond; Masato Yamamoto; Dirk M Nettelbeck; Tanja Hakkarainen; Peter Dall; David T Curiel; Akseli Hemminki
Journal:  Mol Ther       Date:  2006-03-31       Impact factor: 11.454

2.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

Authors:  V N Krasnykh; G V Mikheeva; J T Douglas; D T Curiel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

3.  Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Authors:  Gerd J Bauerschmitz; John T Lam; Anna Kanerva; Kaori Suzuki; Dirk M Nettelbeck; Igor Dmitriev; Victor Krasnykh; Galina V Mikheeva; Mack N Barnes; Ronald D Alvarez; Peter Dall; Ramon Alemany; David T Curiel; Akseli Hemminki
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

4.  Enhanced efficiency and specificity of ovarian cancer gene therapy in rats with a novel nonviral gene delivery system (GE7) via intraovarian artery perfusion approach.

Authors:  Wei Jiang; Cong-Jian Xu; Zhi-Min Shao; Wen-Jiang Zhou; Bin Ye; Pei-Kun Tian; Jin-De Zhu; Jian-Ren Gu
Journal:  Cancer Gene Ther       Date:  2005-10       Impact factor: 5.987

5.  Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.

Authors:  Chandra Bartholomeusz; Hiroaki Itamochi; Linda X H Yuan; Francisco J Esteva; Christopher G Wood; Naoki Terakawa; Mien-Chie Hung; Naoto T Ueno
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

6.  Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer.

Authors:  A Hasenburg; X W Tong; A Rojas-Martinez; C Nyberg-Hoffman; C C Kieback; A Kaplan; R H Kaufman; I Ramzy; E Aguilar-Cordova; D G Kieback
Journal:  Cancer Gene Ther       Date:  2000-06       Impact factor: 5.987

7.  Gene therapy that safely targets and kills tumor cells throughout the body.

Authors:  Alicia Hurtado; Jen-Chieh Tseng; Daniel Meruelo
Journal:  Rejuvenation Res       Date:  2006       Impact factor: 4.663

8.  Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.

Authors:  Zeng B Zhu; Sharmila K Makhija; Baogen Lu; Minghui Wang; Angel A Rivera; Sangae Kim-Park; Ilya V Ulasov; Fen Zhou; Ronald D Alvarez; Gene P Siegal; David T Curiel
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

9.  A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.

Authors:  M A Stoff-Khalili; A A Rivera; J N Glasgow; L P Le; A Stoff; M Everts; Y Tsuruta; Y Kawakami; G J Bauerschmitz; J M Mathis; L Pereboeva; G P Seigal; P Dall; D T Curiel
Journal:  Gene Ther       Date:  2005-12       Impact factor: 5.250

10.  A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.

Authors:  Srinivasan Madhusudan; Ayala Tamir; Nicholas Bates; Elizabeth Flanagan; Martin E Gore; Desmond P J Barton; Peter Harper; Michael Seckl; Hilary Thomas; Nicholas R Lemoine; Mark Charnock; Nagy A Habib; Robert Lechler; Joanna Nicholls; Massimo Pignatelli; Trivadi S Ganesan
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531
View more
  15 in total

1.  A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.

Authors:  Kristopher J Kimball; Meredith A Preuss; Mack N Barnes; Minghui Wang; Gene P Siegal; Wen Wan; Huichien Kuo; Souheil Saddekni; Cecil R Stockard; William E Grizzle; Raymond D Harris; Rosemarie Aurigemma; David T Curiel; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

Review 2.  Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool.

Authors:  Adele Kim; Ilmari Pyykko
Journal:  Mol Cell Biochem       Date:  2011-04-23       Impact factor: 3.396

3.  Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.

Authors:  Sophia Sn Lam; Abby Sc Mak; Judy Wp Yam; Annie Ny Cheung; Hextan Ys Ngan; Alice St Wong
Journal:  Mol Ther       Date:  2014-01-14       Impact factor: 11.454

4.  Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion.

Authors:  Lydia W T Cheung; Susan Yung; Tak-Mao Chan; Peter C K Leung; Alice S T Wong
Journal:  Mol Ther       Date:  2012-11-20       Impact factor: 11.454

5.  Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells.

Authors:  Shufang Chang; Juan Guo; Jiangchuan Sun; Shenyin Zhu; Yu Yan; Yi Zhu; Min Li; Zhigang Wang; Ronald X Xu
Journal:  Ultrason Sonochem       Date:  2012-07-05       Impact factor: 7.491

6.  Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.

Authors:  M Takakura; M Nakamura; S Kyo; M Hashimoto; N Mori; T Ikoma; Y Mizumoto; T Fujiwara; Y Urata; M Inoue
Journal:  Cancer Gene Ther       Date:  2010-01       Impact factor: 5.987

7.  Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.

Authors:  Emily K Mader; Yoshihiro Maeyama; Yi Lin; Greg W Butler; Holly M Russell; Evanthia Galanis; Stephen J Russell; Allan B Dietz; Kah-Whye Peng
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

8.  Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.

Authors:  T Michael Numnum; Sharmila Makhija; Baogen Lu; Minghui Wang; Angel Rivera; Mariam Stoff-Khalili; Ronald D Alvarez; Zeng Bian Zhu; David T Curiel
Journal:  Gynecol Oncol       Date:  2007-12-03       Impact factor: 5.482

9.  A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Authors:  Kenneth H Kim; Igor P Dmitriev; Souheil Saddekni; Elena A Kashentseva; Raymond D Harris; Rosemarie Aurigemma; Sejong Bae; Karan P Singh; Gene P Siegal; David T Curiel; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-06-10       Impact factor: 5.482

10.  Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer.

Authors:  Kristopher J Kimball; Angel A Rivera; Kurt R Zinn; Mert Icyuz; Vaibhav Saini; Jing Li; Zeng B Zhu; Gene P Siegal; Joanne T Douglas; David T Curiel; Ronald D Alvarez; Anton V Borovjagin
Journal:  Mol Imaging       Date:  2009 Sep-Oct       Impact factor: 4.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.